Ontology highlight
ABSTRACT:
SUBMITTER: Sohail A
PROVIDER: S-EPMC5810847 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
Sohail Atif A Mushtaq Adeela A Iftikhar Ahmad A Warraich Zabih Z Kurtin Sandra E SE Tenneti Pavan P McBride Ali A Anwer Faiz F
Immunotherapy 20180201 4
We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy usin ...[more]